Mylan selling generic version of Pfizer’s Detrol

  • Associated Press November 29, 2012

CANONSBURG – Mylan Inc. said Thursday that it is now selling a generic version of Pfizer Inc.’s overactive bladder drug Detrol.

The Southpointe-based company said it started shipping its generic after receiving approval from the Food and Drug Administration. It said U.S. sales of Detrol, or tolterodine, totaled $61.5 million over the year ended Sept. 30.

Mylan plans to start selling a generic version of Detrol LA, a long-acting version of the drug, in early 2014 as part of an agreement with Pfizer. Annual U.S. sales of Detrol LA are around $600 million.

Shares of Pittsburgh-based Mylan rose 13 cents to $27.32 in midday trading after rising as high as $27.45 earlier in the session, its highest since October 2003.


blog comments powered by Disqus

Cyber Monday sales still on top, but losing some luster

Fed moves to bar bailouts of failing firms

Pending homes sales edge up in October

PA Mug Co. owner moves to new studio space in Waynesburg

On the money: Making sure green home upgrades pay off

Dakota city that grew on fracking reaching out for more retail

Super Bowl of shopping unfolds

Coat giveaway better than any Black Friday sale

Orders for U.S. durable goods rise strong 3 percent in October

Applications for U.S. unemployment benefits fall to 260,000